These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19153360)

  • 61. Is hypocalcemia during therapy with zoledronic acid or other bisphosphonates beneficial to cancer patients?
    Tanvetyanon T
    Med Hypotheses; 2004; 63(4):764-5. PubMed ID: 15325030
    [No Abstract]   [Full Text] [Related]  

  • 62. [Zoledronic acid-based uveitis: a case report and a bibliography review].
    Albani-Campanario M; Buendía-Díaz G; Flores-Islas Mde L; Maquita-Nakano C; Ochoa-Cervantes J
    Ginecol Obstet Mex; 2012 May; 80(5):355-9. PubMed ID: 23301428
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Potential effect of zoledronate therapy in heavy proteinuria.
    Gokden N; Zangari M; Elici F; Barlogie B; Kumar J
    Clin Nephrol; 2007 Apr; 67(4):263-5. PubMed ID: 17474565
    [No Abstract]   [Full Text] [Related]  

  • 64. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
    Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
    [TBL] [Abstract][Full Text] [Related]  

  • 65. What is your diagnosis? Osteonecrosis of the jaw; unknown cause(s).
    Rhodus NL
    Northwest Dent; 2009; 88(2):33, 35-7. PubMed ID: 19476043
    [No Abstract]   [Full Text] [Related]  

  • 66. Squamous cell carcinoma complicating epidermolysis bullosa in a 6-year-old girl.
    Shivaswamy KN; Sumathy TK; Shyamprasad AL; Ranganathan C
    Int J Dermatol; 2009 Jul; 48(7):731-3. PubMed ID: 19570079
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Orbital inflammation after zoledronate infusion: an emerging complication.
    Rahimy E; Law SK
    Can J Ophthalmol; 2013 Feb; 48(1):e11-2. PubMed ID: 23419305
    [No Abstract]   [Full Text] [Related]  

  • 68. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
    Lazarovici TS; Yahalom R; Taicher S; Elad S; Hardan I; Yarom N
    J Oral Maxillofac Surg; 2009 Apr; 67(4):850-5. PubMed ID: 19304045
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bilateral Ocular Pain and Hyperemia in a Patient With Paget Disease of the Bone.
    Haider AS; Burbidge AM; Dunlop A
    JAMA Ophthalmol; 2017 Jun; 135(6):665-666. PubMed ID: 28358955
    [No Abstract]   [Full Text] [Related]  

  • 70. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Amnia for intractable skin ulcers with recessive dystrophic epidermolysis bullosa: report of three cases.
    Hasegawa T; Mizoguchi M; Haruna K; Mizuno Y; Muramatsu S; Suga Y; Ogawa H; Ikeda S
    J Dermatol; 2007 May; 34(5):328-32. PubMed ID: 17408442
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of zoledronic acid on bone pain secondary to metastatic bone disease.
    Rotjanapan P
    Med Health R I; 2009 Jan; 92(1):27-9. PubMed ID: 19248423
    [No Abstract]   [Full Text] [Related]  

  • 73. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases.
    Stanton DC; Balasanian E
    J Oral Maxillofac Surg; 2009 May; 67(5):943-50. PubMed ID: 19375001
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Concerns on ranibizumab and zoledronic acid safety for experimentally treating women with endometriosis.
    Barra F; Ferro Desideri L; Gustavino C; Ferrero S; Traverso CE; Nicolò M
    Arch Gynecol Obstet; 2022 Aug; 306(2):569-570. PubMed ID: 34989831
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comprehensive review of bisphosphonate therapy: implications for the oral and maxillofacial surgery patient.
    Ruggiero SL; Carlson ER; Assael LA
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):1. PubMed ID: 19371808
    [No Abstract]   [Full Text] [Related]  

  • 76. Jaw osteonecrosis associated with intravenous bisphosphonate: is incidence reduced after adoption of dental preventive measures?
    Fusco V; Baraldi A; Loidoris A; Ciuffreda L; Galassi C; Goia F; Scoletta M; Berrone S; Benech A; Ortega C; Berruti A;
    J Oral Maxillofac Surg; 2009 Aug; 67(8):1775. PubMed ID: 19615599
    [No Abstract]   [Full Text] [Related]  

  • 77. [Osteonecrosis of the jaw].
    Eriksen EF
    Ugeskr Laeger; 2009 Feb; 171(8):629; author reply 629. PubMed ID: 19291862
    [No Abstract]   [Full Text] [Related]  

  • 78. Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer.
    Bedard PL; Body JJ; Piccart-Gebhart MJ
    J Clin Oncol; 2009 Sep; 27(25):4043-6. PubMed ID: 19652062
    [No Abstract]   [Full Text] [Related]  

  • 79. Laryngeal stenosis in epidermolysis bullosa dystrophica.
    Haruyama T; Furukawa M; Matsumoto F; Kawano K; Ikeda K
    Auris Nasus Larynx; 2009 Feb; 36(1):106-9. PubMed ID: 18479854
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Orthodontic treatment of a patient with recessive dystrophic epidermolysis bullosa: a case report.
    Pacheco W; Marques de Sousa Araugio R
    Spec Care Dentist; 2008; 28(4):136-9. PubMed ID: 18647373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.